BioCryst’s Hereditary Angioedema Candidate Misses Primary Endpoints

BioCryst’s avoralstat failed to meet primary endpoints in the OPuS-2 trial for hereditary angioedema, according to the company.

The company said statistically significant improvements were observed in the higher 500-mg dose for secondary endpoints, which measured quality of life, attack duration and attack severity.